Skip to content

Effects of Citicoline in Patients with Head Trauma

Effect of Citicoline on Level of Consciousness, Serum Level of Fetuin-A and Matrix Gla- Protein (MGP) in Trauma Patients with Diffuse Axonal Injury (DAI) and GCS=8

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201112191840N2
Enrollment
40
Registered
2012-01-18
Start date
2011-09-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head Trauma. Diffuse brain injury

Interventions

Intervention 1: Case group: Drug Citicholine 500 mg/q6h slow IV infusion. Intervention 2: Control group: Without any intervention.
Treatment - Drugs
Case group: Drug Citicholine 500 mg/q6h slow IV infusion

Sponsors

Neuroscience Research Center (NSRC), Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1) 18-65 years of age. 2) Providing informed consent to be included in the study. 3) Absence of major traumatic lesion in chest, abdomen or limbs. 4) Admission within 24 hours following trauma. 5) Absence of major cardiac diseases. 6) Absence of cardiac disease, hyperlipidemia, diabetes and hypertension. Exclusion criteria: 1) Admission after 24 hours following the trauma. 2) History of heart disease, hyperlipidemia, diabetes, hypertension and coagulation disorders. 3) History of malignancy. 4) Multitrauma patients with major trauma of chest, abdomen or limbs. 5) Patients with focal brain lesions such as contusion and brain hematoma which necessitates surgical drainage. 7) Unstable hemodynamic. 8) Pregnancy. 9) Surgery including general, orthopedic or gynecologic surgeries within first 24 hours after trauma. 10) CPR or resuscitation within 24 hours after trauma. 11) Death or discharge within study period.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Fetuin-A. Timepoint: 1st(Before intervention), 6th day(After intervention) and 12th day(After intervention). Method of measurement: Plasma levels.;Matrix Gla Protein (MGP). Timepoint: 1st(Before intervention), 6th(After intervention), 12th day(After intervention). Method of measurement: Plasma levels.;Level of Consciousness. Timepoint: Daily(From the first day of admission to the last day of study). Method of measurement: Assessment of GCS by examiner.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ghaffar Shokouhi

Department of Neurosurgery, Tabriz University of Medical Sciences

shokouhigh@yahoo.com+98 41 1334 0830

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026